U.S. Markets close in 5 hrs 40 mins

OncoSec Medical Incorporated President Punit Dhillon Publishes New Blog Post Titled - Why More Biotechs Should ''Go Social''

OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, published a blog post entitled “Introduction: Why social-digital now?” on Mr. Dhillon’s blog site (punitdhillon.com) which was republished on TheChairmansBlog.com.

OncoSec’s President and CEO, Punit Dhillon, blogs about how social media has changed the landscape of communication between patients, doctors and companies developing therapies for life-threatening conditions. He highlights the importance of adapting to this change by writing, “…to be successful, we are aware that we must be novel in our approach and to take advantage of tools that might not otherwise be traditionally used by companies in our space.” Mr. Dhillon outlines what readers can expect from his blog and encourages feedback via social media.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.